The invention relates to a pharmaceutical composition comprising (i) a live strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp, (ii) an attenuated strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp or, (iii) a medically active substance isolated from a strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp.

The present disclosure provides a method of purifying polysaccharides from a cell lysate, comprising partially purifying the cell lysate comprising an impurity and a polysaccharide to obtain a clarified cmde lysate; mixing the clarified crude lysate with a neutralization solution comprising a salt to form a neutralized lysate; mixing the neutralized lysate with a precipitation solution comprising cetyltrimethylammonium bromide to form a first supernatant and a first precipitate; and separating the first precipitate from the first supernatant, wherein the polysaccharide is located in the first supernatant. The present disclosure further provides a method of making a polysaccharide vaccine. Also provided are vaccines, delivery systems, compositions and polysaccharides made by the methods described herein.

Provided herein are compositions and methods for suppressing pathogenic organisms. Also provided herein are compositions and methods for inducing regulatory T-cells in response to pathogenic organisms and methods of treating a disease or disorder associated with bacterial colonization. Also provided herein are methods of suppressing colonization of the intestine of a subject with oral microbiome bacteria.

Provided herein are compositions and methods for suppressing pathogenic organisms. Also provided herein are compositions and methods for inducing regulatory T-cells in response to pathogenic organisms and methods of treating a disease or disorder associated with bacterial colonization. Also provided herein are methods of suppressing colonization of the intestine of a subject with oral microbiome bacteria.

Disclosed here are phage compositions comprising Type I CRISPR-Cas systems and methods of use thereof. In some embodiments, disclosed herein is a nucleic acid sequence comprising (a) a first CRISPR array designed to be operable with a first Type I CRISPR-Cas system, and (b) a second CRISPR array designed to be operable with a second Type I CRISPR-Cas system, wherein the first Type I CRISPR-Cas system and the second Type I CRISPR-Cas system are different Type I CRISPR-Cas systems.

Disclosed here are phage compositions comprising Type I CRISPR-Cas systems and methods of use thereof. In some embodiments, disclosed herein is a nucleic acid sequence comprising (a) a first CRISPR array designed to be operable with a first Type I CRISPR-Cas system, and (b) a second CRISPR array designed to be operable with a second Type I CRISPR-Cas system, wherein the first Type I CRISPR-Cas system and the second Type I CRISPR-Cas system are different Type I CRISPR-Cas systems.

The present invention relates to a composition, comprising a vinegar pickled egg as an active ingredient, for prevention, alleviation, or treatment of diabetic foot ulcer. More specifically, a vinegar pickled egg fermentate obtained by adding and fermentating egg white of pullet eggs with medicinal herb vinegar does not irritate the skin and is effective for alleviating diabetic foot ulcer, thus being able to find advantageous applications as a therapeutic agent for diabetic foot ulcer, an anti-diabetic foot ulcer skin preparation for external use, or a substance for a health functional food for prevention or alleviation of diabetic foot ulcer.

The present invention relates to a composition, comprising a vinegar pickled egg as an active ingredient, for prevention, alleviation, or treatment of diabetic foot ulcer. More specifically, a vinegar pickled egg fermentate obtained by adding and fermentating egg white of pullet eggs with medicinal herb vinegar does not irritate the skin and is effective for alleviating diabetic foot ulcer, thus being able to find advantageous applications as a therapeutic agent for diabetic foot ulcer, an anti-diabetic foot ulcer skin preparation for external use, or a substance for a health functional food for prevention or alleviation of diabetic foot ulcer.

The disclosure relates generally to bacterial strains of the genus Anaerostipes, e.g., Anaerostipes rhamnosivorans bacterial strains, and compositions, e.g., pharmaceutical compositions, comprising such bacterial strains. The disclosure further relates to method of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis when administered to a subject in need thereof.

The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.